tadalafil has been researched along with Cardiac Failure in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 6 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrade, DR; Claudino, MA; Goncalves, TT; Janussi, SC; Krikorian, K; Mora, AG; Priviero, FBM | 1 |
| Adel, FW; Benike, SL; Burnett, JC; Chen, HH; Hubers, SA; Scott, C; Wan, SH | 1 |
| Cockrill, BA; Ruopp, NF | 1 |
| Skoularigis, J; Starling, RC; Triposkiadis, F; Xanthopoulos, A | 1 |
| Fukumoto, Y; Inoguchi, N; Itaya, N; Kono, S; Kumanomido, J; Nakayoshi, T; Nohara, S; Shimozono, K; Takahashi, J | 1 |
| Beitzke, D; Bouchardy, J; Buechel, RR; Engel, R; Freese, M; Frenk, A; Gabriel, H; Greutmann, M; Haaf, P; Heg, D; Mueller, C; Possner, M; Ruperti-Repilado, FJ; Rutz, T; Schwerzmann, M; Schwitter, J; Schwitz, F; Tobler, D; Trachsel, L; Valsangiacomo Buechel, E; Willhelm, M; Wustmann, K | 1 |
| Baldus, S; Dumitrescu, D; Gerhardt, F; Hellmich, M; Kramer, T; Orlova, K; Rosenkranz, S; Ten Freyhaus, H | 1 |
| Becker, LK; Caldwell, JL; Church, SJ; Dibb, KM; Eisner, DA; Hutchings, DC; Kirkwood, GJ; Lawless, M; Madders, GWP; Pearman, CM; Radcliffe, EJ; Smith, CER; Taylor, RF; Trafford, AW; Unwin, RD; Woods, LS | 1 |
| Chau, VQ; Hoke, NN; Kukreja, RC; Salloum, FN | 1 |
| Burgoyne, JR; Eaton, P; Grover, S; Kass, D; Prysyazhna, O; Scotcher, J | 1 |
| Banasiak, W; Inorowicz, E; Jankowska, EA; Josiak, K; Kremis, E; Ponikowski, P | 1 |
| Aizawa, T; Hatano, M; Inaba, T; Kinugawa, K; Maki, H; Nagai, R; Shiga, T; Yamashita, T; Yao, A | 1 |
| Abassi, Z; Abu-Saleh, N; Armaly, Z; Aronson, D; Assady, S; Awad, H; Bishara, B; Ghrayeb, N; Goltsman, I; Haddad, E; Haddad, S; Khamaysi, I | 1 |
| Kass, DA | 1 |
| Kukreja, RC | 1 |
4 review(s) available for tadalafil and Cardiac Failure
| Article | Year |
|---|---|
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Topics: Adult; Antihypertensive Agents; Endothelin Receptor Antagonists; Endothelins; Guanosine Monophosphate; Heart Failure; Humans; Hypertension, Pulmonary; Infant, Newborn; Nitric Oxide; Pulmonary Arterial Hypertension; Tadalafil; United States | 2022 |
Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
Topics: Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Guanosine Monophosphate; Guanylate Cyclase; Heart Failure; Humans; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Retrospective Studies; Sildenafil Citrate; Soluble Guanylyl Cyclase; Tadalafil; Vasodilator Agents | 2022 |
[Is there a place for treatment with type 5 phosphodiesterase inhibitors in heart failure patients?].
Topics: Carbolines; Heart Failure; Humans; Imidazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfones; Tadalafil; Treatment Outcome; Triazines; Vardenafil Dihydrochloride | 2011 |
Cardiac role of cyclic-GMP hydrolyzing phosphodiesterase type 5: from experimental models to clinical trials.
Topics: Carbolines; Cardiomyopathy, Dilated; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 5; Fibrosis; Heart; Heart Failure; Humans; Hypertrophy; Myocardium; Phosphodiesterase 5 Inhibitors; Phosphoric Diester Hydrolases; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Transforming Growth Factor beta; TRPC Cation Channels; Ventricular Remodeling | 2012 |
2 trial(s) available for tadalafil and Cardiac Failure
| Article | Year |
|---|---|
Cardiorenal Effects of Long-Term Phosphodiesterase V Inhibition in Pre-Heart Failure.
Topics: Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Glomerular Filtration Rate; Heart Failure; Humans; Natriuretic Peptide, Brain; Sodium; Tadalafil | 2022 |
Effect of phosphodiesterase-5 inhibition on SystEmic Right VEntricular size and function. A multicentre, double-blind, randomized, placebo-controlled trial: SERVE.
Topics: Adult; Cyclic Nucleotide Phosphodiesterases, Type 5; Double-Blind Method; Female; Heart Failure; Heart Ventricles; Humans; Middle Aged; Stroke Volume; Tadalafil; Transposition of Great Vessels; Ventricular Function, Right | 2023 |
9 other study(ies) available for tadalafil and Cardiac Failure
| Article | Year |
|---|---|
Tadalafil treatment improves cardiac, renal and lower urinary tract dysfunctions in rats with heart failure.
Topics: Animals; Heart Failure; Kidney; Lower Urinary Tract Symptoms; Male; Oxidation-Reduction; Rats; Rats, Sprague-Dawley; Tadalafil; Urinary Bladder | 2022 |
Effects of Low-Dose Tadalafil in a Patient with Biventricular Heart Failure: A Case Report.
Topics: Aged; Cardiac Output, Low; Heart Failure; Hemodynamics; Humans; Male; Phosphodiesterase 5 Inhibitors; Tadalafil | 2023 |
Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension.
Topics: Aged; Cardiac Catheterization; Echocardiography; Female; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hypertension, Pulmonary; Male; Phosphodiesterase 5 Inhibitors; Retrospective Studies; Stroke Volume; Tadalafil; Time Factors; Treatment Outcome; Vascular Resistance; Ventricular Function, Right | 2019 |
Phosphodiesterase 5 inhibition improves contractile function and restores transverse tubule loss and catecholamine responsiveness in heart failure.
Topics: Animals; Catecholamines; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Female; Heart Failure; Induced Pluripotent Stem Cells; Myocardial Contraction; Myocytes, Cardiac; Phosphodiesterase 5 Inhibitors; Sheep; Tadalafil; Ventricular Remodeling | 2019 |
Tadalafil prevents acute heart failure with reduced ejection fraction in mice.
Topics: Animals; Apoptosis; Carbolines; Cardiomegaly; Cardiomyopathies; Coronary Vessels; Heart Failure; Male; Mice; Mice, Inbred ICR; Myocardial Infarction; Phosphodiesterase Inhibitors; Pulmonary Edema; Tadalafil; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Iα Oxidation.
Topics: Animals; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinase Type I; Cyclic Nucleotide Phosphodiesterases, Type 5; Disulfides; Doxorubicin; Heart Failure; Mice; Mice, Mutant Strains; Oxidation-Reduction; Phosphodiesterase 5 Inhibitors; rho-Associated Kinases; Second Messenger Systems; Tadalafil | 2016 |
Initial and programmed combination therapy with oral drugs for severe idiopathic pulmonary arterial hypertension.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Carbolines; Cardiac Output; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Echocardiography; Electrocardiography; Epoprostenol; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Middle Aged; Sulfonamides; Tadalafil; Vasodilator Agents | 2011 |
Phosphodiesterase 5 inhibition protects against increased intra-abdominal pressure-induced renal dysfunction in experimental congestive heart failure.
Topics: Animals; Carbolines; Cardio-Renal Syndrome; Disease Models, Animal; Glomerular Filtration Rate; Heart Failure; Hemodynamics; Intra-Abdominal Hypertension; Kidney; Male; Phosphodiesterase 5 Inhibitors; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Renal Plasma Flow; Tadalafil | 2012 |
Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Animals; Antihypertensive Agents; Carbolines; Cardiomyopathies; Cardiovascular Agents; Cyclic Nucleotide Phosphodiesterases, Type 5; Disease Models, Animal; Doxorubicin; Endothelium, Vascular; Enzyme Inhibitors; Erectile Dysfunction; Heart Failure; Humans; Hypertension; Hypertension, Pulmonary; Imidazoles; Male; Myocardial Infarction; Myocardial Reperfusion Injury; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfones; Tadalafil; Triazines; Vardenafil Dihydrochloride; Vasodilator Agents; Ventricular Remodeling | 2007 |